Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $147M | $317M | $152M | $196M | $268M | $443M | $660M | $829M | $1.02B | $1.40B |
| Revenue growth | — | 115.8% | -52.0% | 29.1% | 36.5% | 65.7% | 48.9% | 25.6% | 22.4% | 37.6% |
| Operating income | -$83.2M | $81.0M | -$69.3M | -$67.6M | $144M | $276M | $268M | $338M | $551M | $469M |
| Operating margin | -56.7% | 25.6% | -45.7% | -34.5% | 53.9% | 62.2% | 40.5% | 40.7% | 54.3% | 33.6% |
| Net income | -$103M | $63.0M | -$80.3M | -$72.2M | $129M | $403M | $202M | $282M | $444M | $317M |
| Net margin | -70.2% | 19.9% | -52.9% | -36.9% | 48.2% | 90.8% | 30.6% | 34.0% | 43.7% | 22.7% |
| EPS (diluted) | -$0.81 | $0.45 | -$0.56 | -$0.50 | $0.91 | $2.74 | $1.44 | $2.10 | $3.43 | $2.56 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$50.4M | $134M | -$49.5M | -$85.4M | $55.5M | $299M | $240M | $389M | $479M | $652M |
| Capital expenditures | $3.14M | $1.35M | $4.66M | $4.04M | $2.50M | $1.46M | $4.81M | $15.3M | $10.7M | $6.97M |
| Free cash flow | -$53.5M | $133M | -$54.2M | -$89.5M | $53.0M | $298M | $235M | $373M | $468M | $645M |
| Share buybacks | — | $0.00 | $0.00 | $200M | $150M | $350M | $200M | $402M | $250M | $342M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $66.8M | $169M | $57.9M | $120M | $148M | $119M | $234M | $118M | $116M | $134M |
| Total assets | $262M | $520M | $440M | $566M | $580M | $1.10B | $1.84B | $1.73B | $2.06B | $2.53B |
| Total liabilities | — | — | — | — | — | — | $1.67B | $1.65B | $1.70B | $2.48B |
| Long-term debt | $199M | $125M | $34.9M | $383M | $0.00 | $787M | $1.49B | $1.50B | $1.51B | $2.14B |
| Shareholders' equity | -$32.5M | $208M | $249M | $91.8M | $151M | $197M | $170M | $83.8M | $364M | $48.8M |
| Retained earnings | -$585M | -$522M | -$531M | -$604M | -$475M | -$58.9M | $143M | $90.5M | $360M | $54.8M |
| Shares (wtd avg diluted) | 128M | 139M | 144M | 144M | 141M | 147M | 141M | 134M | 129M | 124M |
Every figure is extracted from HALOZYME THERAPEUTICS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.